Matrix catabolism in arthritis: priming the guns with oncostatin M.
Richards
Carl D
CD
D000818:Animals; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D004195:Disease Models, Animal; D005109:Extracellular Matrix / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D007375:Interleukin-1 / Q000378:metabolism*; D051379:Mice; D053683:Oncostatin M; D010455:Peptides / Q000187:drug effects / Q000378:metabolism*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000378:metabolism*
D018501:Antirheumatic Agents; D018836:Inflammation Mediators; D007375:Interleukin-1; C508351:OSM protein, human; C508352:Osm protein, mouse; D010455:Peptides; D014409:Tumor Necrosis Factor-alpha; D053683:Oncostatin M